Cue Biopharma, a preclinical biotech developing T cell immuno-oncology therapies, filed for an initial public offering on Thursday. The deal is being underwritten on a min-max, "best efforts" basis, and will therefore be excluded from our IPO stats.
The Cambridge, MA-based company plans to raise $35 to $40 million by offering a 5.0 to 5.7 million shares at a price range of $6 to $8. At the midpoint of the proposed ranges, Cue Biopharma would raise $37.5 million at a market value of $117 million.
Cue Biopharma was founded in 2014 and plans to list on the Nasdaq under the symbol CUE. MDB Capital Group and Feltl and Company are the joint bookrunners on the deal.
